We give you a written timeline estimate for your case before you commit.Get my quote
Fayuvi (rebisufligene etisparvovec-hopf): what it is and how families in the Gulf can get it
Plain facts from FDA and manufacturer sources, and the legal routes for families in the Gulf.
Reviewed by the Reserve Meds clinical operations team on 13 October 2026.
The short answer
Fayuvi (rebisufligene etisparvovec-hopf) is an FDA-approved one-time AAV9 gene therapy made by Ultragenyx Pharmaceutical. The FDA approved it on 17 September 2026 for Sanfilippo syndrome type A (MPS IIIA) in children. At approval, Fayuvi was approved only in the United States. Ultragenyx announced in October 2026 that it had submitted a marketing application to the European Medicines Agency. We found no Gulf registration in public sources as of 13 October 2026. It is given only at specialized treatment centers, so for most Gulf families the realistic route is treatment at a qualified center abroad after a specialist referral. A local hospital can only give it if the manufacturer agrees to supply it and the national regulator approves the import. Plan in months, not weeks (our estimate, not a promise).
About Fayuvi
- Generic name: rebisufligene etisparvovec-hopf
- Made by: Ultragenyx Pharmaceutical
- US FDA approval: 17 September 2026
- Approved for: the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function
- How it is given: a single intravenous (IV) infusion, given in a specialized healthcare setting
It is the first FDA-approved treatment for Sanfilippo syndrome type A. Ultragenyx said the FDA granted standard (full) approval. The treating team will explain the monitoring needed before and after a gene therapy infusion.
Country guides
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate access to FDA-approved medicines only. We help your doctor and hospital prepare the request, arrange US supply and shipping once approval is in place, and keep your family updated. We do not prescribe or give medical advice. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
Ask about Fayuvi
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
What is Fayuvi?
Fayuvi (rebisufligene etisparvovec-hopf) is a one-time AAV9 gene therapy made by Ultragenyx Pharmaceutical. The US FDA approved it on 17 September 2026 for the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function.
Is Fayuvi approved outside the United States?
At approval, Fayuvi was approved only in the United States. Ultragenyx announced in October 2026 that it had submitted a marketing application to the European Medicines Agency. We found no registration in Saudi Arabia, the UAE, Kuwait or Qatar in public sources as of 13 October 2026. A hospital pharmacy should confirm with the national regulator.
Can families in the Gulf get Fayuvi?
Usually by treatment at a qualified center abroad, after a specialist referral. A local hospital can give it only if the manufacturer agrees to supply it and the regulator approves the import.
How much does Fayuvi cost?
Medicine price: quote on request. Your total cost is quoted in writing for your case before you commit. No hidden charges.
What does Reserve Meds do?
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate the paperwork, supply and shipping with your doctor and hospital. We do not prescribe or give medical advice.
Sources
Checked on 13 October 2026. Regulator rules change. Your hospital pharmacy confirms the current procedure before filing.
- FDA: FAYUVI (rebisufligene etisparvovec-hopf) product page, approved 17 Sep 2026
- Ultragenyx: approval of FAYUVI gene therapy, 17 Sep 2026 (press release via Finviz)
- WebMD: FDA approves Fayuvi (single IV infusion in a specialized healthcare setting)
- PharmaKnowl: Named Patient Program in Saudi Arabia (reference regulators, hospital and importer declarations, patient consent)
- Baker McKenzie: new Emirates Drug Corporation replaces MOHAP as federal regulator of medical products (Federal Decree No. 28 of 2023)
- Al Tamimi & Co: Kuwait Ministry of Health restrictions on the supply of non-registered medical products (Resolution No. 100 of 2023)
- Qatar Ministry of Public Health: services for companies (pharmacy and drug control)